http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2013000824-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d256a71b48c66dc1996ef9368d6ac8a2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 |
| filingDate | 2011-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e42d174cb0fef7970c04a77882882b1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8374e344234a1fe379fe9cad1a861e3d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_064c0f7f6edc1950debba565aa74423c |
| publicationDate | 2013-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-2013000824-A |
| titleOfInvention | UNIQUE DAILY DOSAGE FORM FOR THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME. |
| abstract | The present invention belongs to the fields of medicine, pharmaceutical, nutraceutical, endocrinology and cardiology. The invention provides compositions comprising a statin, an angiotensin converting enzyme inhibitor, an antiplatelet compound and a hyperglycemic compound for use in the treatment and / or prevention of cardiometabolic risk factors for Metabolic Syndrome and in the treatment and / or Metabolic Syndrome prevention. The present invention refers to the use of such compositions in the manufacture of products for the treatment and / or prevention of Metabolic Syndrome. Metformin biguanide of the composition could be present in the form of prolonged release, which would allow its use together with the other drugs in a single dose form and at low doses. This combination of drugs in a single daily dosage form greatly improves patient compliance with the treatment regimen and their adherence to treatment, which is an essential factor in the treatment of patients with Metabolic Syndrome. |
| priorityDate | 2010-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 488.